OrbiMed To Raise $450 Million For Third Asia Life Science Fund Post author:Sam Post published:March 2, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Bay Area Rigel's CFO to Exit, Effective Dec. 31, 2017 December 14, 2017 FDA Grants Yisheng Biopharma's Clinical Treatment its Second Orphan Drug Designation February 25, 2018 Innate Pharma Regroups From Trial Failure With €410 Million Deal For Novo Nordisk A/S's AntiC5aR Antibody June 4, 2017
FDA Grants Yisheng Biopharma's Clinical Treatment its Second Orphan Drug Designation February 25, 2018
Innate Pharma Regroups From Trial Failure With €410 Million Deal For Novo Nordisk A/S's AntiC5aR Antibody June 4, 2017